

Article

A Preliminary Attempt at the Identification and Financial Estimation of the Negative Health Effects of Urban and Industrial Air Pollution Based on the Agglomeration of Gdańsk

Piotr O. Czechowski ^{1, *}, Piotr Dąbrowiecki ², Aneta Oniszczyk-Jastrząbek ³,
Michalina Bielawska ⁴, Ernest Czermanski ³, Tomasz Owczarek ¹, Patrycja Rogula-Kopiec ⁵
and Artur Badyda ⁶

¹ Faculty of Entrepreneurship and Quality Science, Department of Management and Economics, Department of Quantitative Methods and Environmental Management, Gdynia Maritime University, 81-225 Gdynia, Poland; t.owczarek@wpit.umg.edu.pl

² Military Institute of Medicine, Clinic of Infectious Diseases and Allergology, 00-144 Warsaw, Poland; pdabrowiecki@wim.mil.pl

³ Faculty of Economics, University of Gdańsk, 81-824 Sopot, Poland; ekoao@ug.edu.pl (A.O.J.); e.czermanski@ug.edu.pl (E.C.)

⁴ Agency of Regional Monitoring Atmosphere of Gdańsk Agglomeration, Brzozowa 15 A, 80-243 Gdańsk, Poland; michalina@armaag.gda.pl

⁵ Institute of Environmental Engineering, Polish Academy of Sciences, 41-819 Zabrze, Poland; patrycja.rogula-kopiec@ipis.zabrze.pl

⁶ Faculty of Building Services, Hydro- and Environmental Engineering, Warsaw University of Technology, Department of Informatics and Environment Quality Research, 00-653 Warsaw, Poland; artur.badyda@pw.edu.pl

* Correspondence: p.o.czechowski@wpit.umg.edu.pl; Tel.: +48-502-085-307

Received: 16 November 2019; Accepted: 16 December 2019; Published: 19 December 2019

Abstract: This article marks the first attempt on Polish and European scale to identify the relationship between urban and industrial air pollution and the health conditions of urban populations, while also estimating the financial burden of incidence rates among urban populations for diseases selected in the course of this study as having a causal relation with such incidence. This paper presents the findings of a pilot study based on general regression models, intended to explore air pollutants with a statistically relevant impact on the incidence of selected diseases within the Agglomeration of Gdańsk in the years 2010–2018. In discussing the city's industrial functions, the study takes into consideration the existence within its limits of a large port that services thousands of ships every year, contributing substantially to the volume of emissions (mainly NO_x and PM) to the air. The causes considered include the impact of air pollution, seasonality, land- and sea-based emissions, as well as their mutual interactions. All of the factors and their interactions have a significant impact ($p \leq 0.05$) on the incidence of selected diseases in the long term (9 years). The source data were obtained from the Polish National Health Fund (NFZ), the Agency for Regional Monitoring of Atmosphere in the Agglomeration of Gdańsk (ARMAAG), the Chief Inspectorate of Environmental Protection (GIOŚ), and the Port of Gdańsk Harbourmaster. The study used 60 variables representing the diseases, classified into 19 groups (Appendix A, Figure A1). The resulting findings were used to formulate a methodology for estimating the financial burden of the negative health effects of air pollution for the agglomeration, and will be utilized as a reference point for further research in selected regions of Poland.

Keywords: air pollution; health effects of air pollution; statistics; GRM model; COPD; costs of health loss by air emission; asthma; respiratory infections

1. Introduction

1.1. Aim of the Research

The main object of this paper is to precisely identify the adverse health effects of air pollution reported in urban and industrial agglomerations, both in quantitative terms (incidence) and financial terms (cost burden of medical treatment) in the region's sustainable development policy.

To accomplish this objective, a precise identification has to be made of the diseases related to air pollution and their causes. At this stage, the research project focuses on the air pollution aspect. The problem of air pollution has remained unnoticed for many years, leading to an accumulation of hazards with a direct health impact, such as smog episodes. The cause-and-effect mechanism behind this phenomenon is not adequately studied, with the literature only naming potential causes but providing little indication as to their long-term influence on human health.

1.2. Motivation

Polish cities with different degrees of air pollution problems, such as Warsaw [WAW], Tricity (Gdańsk, Sopot and Gdynia) [TRJ], Cracow [KRA], Zabrze [ZAB] and Nowy Sacz [NSA], have been selected as case studies for the identification of statistically relevant factors behind particularly health-threatening diseases. A relatively long nine-year period (2010–2018) has been considered so as to identify the direct cause-and-effect relationships, as well as determine the long-term effects of exposure to a polluted environment, while also taking into account the interactions between pollutant concentrations, weather conditions and time of exposure. The results for Tricity will set the stage for studies on other urban areas. Besides the reasons discussed above, Tricity has been selected as a pilot case study because of its seaside location and the influence of other factors associated with sea port emissions, in particular, those attributable to ships (engine exhaust emissions from arriving/departing ships and exhaust from power generators in ships moored at berth).

A precise identification of the factors requires the use of statistical tools. Of these, the most fundamental one is the reference grid of the automatic air monitoring system. Of all the cities concerned, the most extensive grid is found in Tricity. The grid should ensure that measurements are reliable so as to enable the data derived from them to be utilized for exploring models of health impact with key implications for city residents. Statistical methodology is of prime importance for this purpose [1].

The use of quantitative methods, including stochastic and exploratory techniques, in environmental studies does not seem to be sufficient for practical purposes. There is no comprehensive dedicated analytical system to address this issue, or research regarding this subject. The methodological emphasis at the initial stage of work was placed on data quality assessment through the authors' own data quality method [2]—using harmonic models and robust estimators in addition to the classical tests of outlier values with their iterative expansions. The results obtained demonstrate both the complementarity of the proposed solution in relation to classical methods as well as allowing a significant extension of the range of applications. The practical usefulness is also highly significant due to the high effectiveness and numerical efficiency as well as the simplicity of this new tool.

1.3. Global Background and Local Air Quality Problems

According to UNFPA (United Nations Population Fund), the world's population reached 7.715 billion in 2019. On a global scale, urban residents make up over 50% of the overall worldwide population. The same figure stands at approximately 75% for Europe alone. Moreover, estimates show that, by 2030, the world population (which will by then reach 8.5 billion) will include 5 billion

city dwellers (over 60%) [3]. This means that the maintenance of air quality, especially in large urban areas, will be an increasingly serious challenge for institutions and governing bodies managing the quality of the environment. In various locations in the world, as indicated by the World Health Organization's data (WHO Global Ambient Air Quality Database), air quality deviates significantly not only from the rather restrictive WHO guidelines, but also from the usually more liberal local legal regulations. As a result, 92% of the world's population lives in conditions where the WHO standards are exceeded [4]. This in turn causes ambient air pollution to account for an estimated 4.2 million deaths per year due to stroke, heart disease, lung cancer and chronic respiratory diseases. Although the most unfavorable situation applies to some Asian and African countries and the Middle East, Poland is one of the most polluted countries in the European Union.

As a consequence of the relatively high emissions of air pollutants in Poland, limit values of particulate matter (PM₁₀ and PM_{2.5}) concentrations (according to 2004/107/EC Directive) [5] as well as benzo(a)pyrene (BaP) target values (according to 2008/50/WE Directive) [6] are regularly exceeded. In some areas (a relatively small number (4–6) of locations), calendar year limit values for nitrogen dioxide (NO₂) as well as target values for ozone (O₃) and arsenic (As) are also not complied with. The principal sources of air pollutant emissions to ambient air include the municipal and household sector as well as road transport. According to the European Environmental Agency's (EEA) Air Pollutant Emissions Data Viewer (most recent data from 2017), the municipal and household sector in Poland in 2017 was mostly responsible for the emission of PM₁₀, PM_{2.5} and carbon monoxide (CO). The annual emission of PM₁₀ was 125,082 tons (Mg) (which is 50.8% of the total national emission), of PM_{2.5} was 78,937 tons (53.6% of the total emission), and of CO was 1,598,900 tons (62.9% of the total emission). The highest share of this sector in the total emission balance concerns the benzo(a)pyrene–commercial and household sector, due to the fact that solid fuel (mainly coal and wood) incineration is responsible for 83.6% of the total BaP national emission (i.e., 34 tons). Meanwhile, road transportation is primarily responsible for nitrogen oxides (NO_x) and CO emission. The annual national emission of NO_x in 2017 accounted for 297,356 tons (which is 37.0% of the total national emission), and of CO was 588,444 tons (23.1% of the total emission). These two sectors of the Polish economy overwhelmingly shape the air quality, although the impact on the so-called background concentration also involves the sectors of energy production and distribution as well as industrial processes and product use.

A quantitative (model) identification of diseases arising from long-term exposure (more than 9 years) to air pollution has never been made in Poland. Such identification will allow the estimation of the actual financial burden of air pollution to society.

This paper is an interdisciplinary project addressing three main areas of concern: health, environment and economy. The three aspects are interconnected from a statistical perspective and hard-wired into information systems currently under construction. The wide thematic scope of this project will allow us to address only certain Gdańsk-specific questions with key implications for the achievement of the research objectives set out in this paper.

1.4. Social Background of the Issue and Literature Review

This section focuses on air pollution as one of the most dangerous environmental impacts on the development and functioning of the respiratory system. The key respiratory diseases include: asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections.

Research shows that both short- and long-term exposure to common air pollutants at elevated concentrations is associated with heightened incidence and mortality rates for respiratory diseases [7,8]. One of the key pollutants with adverse effects on the respiratory tract is suspended particulate matter. Depending on particle size, suspended matter may penetrate various parts of the respiratory tract. Particulate matter deposits in the upper parts of the respiratory tract may aggravate the symptoms of asthma and COPD [9]. Water-soluble gaseous pollutants (e.g., SO₂) are absorbed mainly in the upper parts of the respiratory tract, promoting damage to upper airways and primary bronchi. Gases with lower water solubility (e.g., NO₂ and O₃) mainly affect the lower respiratory tract [10].

Bronchial asthma is estimated to affect approximately 235 million people globally, causing 345 thousand deaths every year [11]. The sharp increase in the worldwide incidence of asthma, especially in industrialized countries, has made it the most frequent chronic children's disease [12].

Chronic obstructive pulmonary disease (COPD) is characterized by partially irreversible restriction of airflow through the respiratory tract, triggering an inflammatory response to various harmful substances [13]. COPD is a major problem in developing and developed countries alike. Estimates suggest that, in 2020, the condition will have become the world's third leading cause of death and the fifth cause of motor impairment or even disability, generating high social and economic costs [14]. Poland has a high number of COPD and asthma sufferers (estimated at approx. 6 million in total), 80% of whom have not been adequately diagnosed and therefore not offered proper medical attention [15,16]. Smoking tobacco remains the largest risk factor for COPD, accounting for 80% of instances of this illness [14]. This is followed by exposure to occupational hazards and to polluted air [14,17]. However, COPD also affects non-smokers. Research conducted in the USA under the NHANES III project found that 19.2% of diagnosed cases of COPD among 10 thousand adults aged 30–75 were attributable to exposure to polluted air in the workplace. In the sample of non-smokers, exposure to occupational hazards accounted for 31.1% of cases of COPD [18]. The increase in COPD incidence worldwide cannot be satisfactorily accounted for solely by smoking tobacco without regard to any other factors [17].

Exposure to air pollutants substantially increases the incidence of respiratory infections, including pneumonia, especially in children [19] and the elderly [20]. It is noteworthy that pneumonia is among the leading causes of death in developed countries. As for the elderly, some studies argue that a link exists between short-term exposure to air pollutants and incidence of pneumonia [21,22]. Long-term exposure to air pollutants has also been shown to be a risk factor for respiratory infections. A survey conducted in Hamilton (Canada) on subjects aged over 65 revealed a correlation between heightened exposure to nitrogen dioxide and/or PM_{2.5} and an increased number of hospitalizations for pneumonia [22,23].

1.5. Economic Background of the Issue and Literature Overview

The economic effects of health loss due to diseases related to air pollution may be studied from a number of perspectives: financial (lost earnings), social (lost GDP), social insurance (pay-out on health insurance and disability pensions), and taxpayer (National Health Fund, Ministry of Health). The analysis considers direct (medical and non-medical) costs, indirect costs, and social costs representing the total burden to the patient and to the economy as a whole. Direct costs are financial burdens to society in the form of money transfers from the healthcare system to entities providing medical services. This cost group represents the main cost component of illness, as it takes the form of cash transfers flowing from the National Health Fund to hospitals or from patients to hospitals. These are not the only costs of illness, however. There are also indirect costs, which make up more than half of total medical costs [24], broadly defined as production losses [25]. Additionally, the indirect costs component also includes the costs of out-of-system medical care, costs of free-of-charge labor, compensation mechanisms, and the group dependency effect [26]. It is noteworthy that indirect costs of medical care are usually related to disease itself, while direct costs are usually associated with the treatment process or preventive measures. Therefore, by footing direct costs, it is possible to reduce indirect costs.

Due to a lack of financial data on procedures funded by the National Health Fund, this article will focus on the first group of costs, i.e., direct costs of medical treatment.

2. Materials and Methods

Primary data drawn from the following sources have been used to construct statistical models:

Health data—National Health Fund database covering the period from 1 January 2010 to 31 December 2018 on all health services rendered in Poland by region (14,387,846 services).

Air pollution data—hourly data for the Tricity area collected from five measurement stations located within the Agglomeration of Gdańsk (AM2, AM3, AM5, AM6 and AM8) for the period from 2010 to 2018 (Figure 1).




Figure 1. Location of measurement stations within the Agency of Regional Monitoring of Atmosphere in the Agglomeration of Gdańsk (ARMAAG) network utilized in the study.

The stations are located close to the Bay of Gdańsk. This study includes gaseous pollutants (sulfur dioxide, nitrogen dioxide, nitrogen oxides, ozone, carbon oxide and carbon dioxide), particulate pollutants (PM₁₀ and PM_{2.5}) as well as weather parameters (temperature, relative air humidity, wind force and direction, and rainfall). Additional data on benzo(a)pyrene from the Chief Inspectorate of Environmental Protection’s manually operated station in Gdańsk, covering the period from 1 January 2010 to 21 December 2018, have been copied from the air quality website at <http://powietrze.gios.gov.pl/pjp/archives>.

Ship traffic data come from the port of Gdańsk (54°25′N, 18°39′E) and cover the period from 1 January 2010 to 6 November 2017.

All of the data have been entered into a single database after being counted and added up (health data, ship traffic data) or averaged (Agency for Regional Monitoring of Air Pollution, Chief Inspectorate of Environmental Protection). The article utilizes a number of statistical methods and models (analysis of variance, ANOVA; analysis of co-variance, ANCOVA; Cluster Analysis, CA; Principal Component Analysis models, PCA; and others), of which GRMs (Generalized Regression Models) are the most important.

GRMs are an extension of the GLM (Generalized Linear Model) family. A general linear model may be treated as an extension of multiple linear regression for a single dependent variable. The multiple regression model underlies general linear regression. The general purpose of multiple regression (a term first used by Pearson in 1908) is to give a qualitative overview of relationships between multiple independent (controlled, explanatory) variables and dependent (criterion, explained) variables.

The basic multiple regression model in its general form is as follows:

$$Y = b_0 + b_1X_1 + b_2X_2 + \dots + b_kX_k \quad (1)$$

where:

Y —explained variable;

k —number of predictors (controlled variables).

Contrary to the multiple regression model, which is more suitable for analyzing continuous predictors (strong measurement scales, such as weather measurements or pollutant concentration measurements), the general linear model can be more readily applied to any instance of analysis of variance (ANOVA) featuring qualitative (categorized) predictors, to any instance of analysis of co-variance (ANCOVA) featuring qualitative (categorized) predictors, such as heating periods or rainfall, as well as any model of regressive analysis featuring continuous predictors.

In the case of qualitative predictors, the outcomes may be coded in experiment matrix X , using a re-parameterized model or a sigma-limiting model.

Contrary to other models, the Generalized Linear Regression Model is not a model in a strict sense, but a modeling pathway comprising a variety of model classes and estimation methods:

- Simple regression
- Multiple regression
- Factor regression
- Polynomial regression
- Response surface regression
- Response surface regression for mixtures
- Single-factor ANOVA
- Main effects ANOVA
- Factorial ANOVA
- Analysis of co-variance (ANCOVA)
- Identical slopes model

GRM consolidates all these models and allows for identification of a cause-and-effect relationship regardless of the measurement scale of independent variables.

The first step in model quality assessment is to verify how well empirical data fit into a model, that is to say, to test the goodness of fit, with the available error measures applied. The most commonly used metric for good fit assessment is the determination co-efficient:

$$R^2 = 1 - \frac{n-1}{n-k-1} \left(1 - \frac{\sum_{t=1}^n (\hat{x}_t - \bar{x})^2}{\sum_{t=1}^n (x_t - \bar{x})^2} \right) \quad (2)$$

where:

x_t —values of variable X at time or period t ,

\hat{x}_t —theoretical value of variable X at time or period t ,

\bar{x} —mean value of variable X in a time series on n observations,

n —number of observations,

k —number of explanatory variables.

This metric shows the goodness of the model's fit with the empirical data. Its primary advantage is normalization. In fact, the metric is simply an adjusted coefficient of determination based on the "penal factor," favoring multivariate models with fewer independent variables. In this study, this metric also plays an explanatory role in that it specifies what portion of the information pool on disease incidence variability could be accounted for by the model and therefore also to what extent the identified predictors account for total disease incidence variability.

The evaluation of model errors, expressed as root mean square of the error, holds a central place in model quality assessment:

$$\text{RMSE} = \sqrt{\text{MSE}} = \sqrt{\frac{1}{n} \sum_{t=1}^n e_t^2} \quad (3)$$

where:

$e_t = x_t - \hat{x}_t$ —model remainders.

This metric shows how far the actual values deviate from theoretical values determined in the model. Useful, though not always accurate, information can also be extracted from the random-error-based variability coefficient reflecting the mean level of the phenomenon:

$$V(S_e) = \frac{RMSE}{\bar{x}} \cdot 100 \quad (4)$$

The formula gives an idea of the root mean square error concentration within the medium level. AICC (Akaike Information Criterion with correct for small size sample) criteria are generalized FPE (Akaike's Final Prediction Error Criterion) criteria proposed by Akaike.

$$AICC(\beta) := -2\ln L_x\left(\beta, \frac{S_x(\beta)}{n}\right) + \frac{2(p+q+1)n}{(n-p-q-2)} \quad (5)$$

The AICC criteria differ from AIC (Akaike Information Criterion) in weighting adjustment. AIC and AICC statistics are based on the quotient of the maximum likelihood function. Criterion design is done by comparing the estimated model with the full (ideal) model. The model with the lowest criterion value is thought to be the best.

Eventually, the formula proposed by Makridakis as an extension of the previous variants was adopted as the key selection criterion:

$$AICC = n(1 + \log(2\pi)) + n \cdot \ln \hat{\sigma}_k^2 + 2k \quad (6)$$

The calculation methodology adopted in the economic section comprises aggregated cost categories, such as medical care costs, hospitalization costs, diagnostic costs, medication costs and costs of specialist consultancy services provided to in-patients in all hospitals in Gdańsk and Gdynia within the period in question. This breakdown into five cost categories is consistent with the standards for calculation of medical treatment costs adopted by Polish medical service providers as the basis for charging fees for contracted treatments. The value data have been drawn from a register of services subsidized by the National Health Fund and provided by the Clinic of Infectious Diseases and Allergology at the Military Institute of Medicine in Warsaw in 2018 for diseases selected in the course of this study as being correlated with air pollution in urban agglomerations. The classification includes a calculation of total medical costs of specific diseases, expressed as the combined products of lump-sum financial costs disclosed by the service provider. The data have been additionally refined by the inclusion of refund amounts paid monthly by the National Health Fund to medical service providers for each completed procedure relating to diseases covered by the register.

3. Results

For all the relevant diseases represented by the variables in the first column (Table 1), the percentage of valid observations (column “% Valid Obs”) and basic distribution characteristics (asymmetry and kurtosis) have been calculated. The column “standard Normality tests” contains the results of a Kolmogorov–Smirnov [K–S] test, a K–S with Lilliefors correction and of a Shapiro–Wilk Francia test with Royston correction. The columns “Distribution 1st Similar” and “Distribution 2nd Similar” contain estimation results by the Maximum Likelihood estimation of the two most similar distributions based on the Minimum Likelihood Criterion. The tests have show a deviation from the normal distribution of variables without their levels being considered. For all variables, the Normal distribution (with possible Box–Cox logarithmic transformations) is the best empirical approximation of the investigated variables; therefore, it has been assumed that the distributions of empirical variables are largely similar to the normal distribution.

The next step was to identify, for each disease, factor models in relevant correlation with incidence rates for a specific disease (Table 2) without singling out emissions of maritime origin and factor models considering only sea winds (emissions of maritime origin) (Table 3). A comparison of outcomes derived from the two models leads to clear conclusions regarding emissions of maritime or port origin with health impact on urban populations.

Table 1. Selected numerical data on the incidence of diseases within the Agglomeration of Gdańsk [TRJ] in the years 2010–2018 (an abbreviations list of the names of Variables can be found in Appendix A); abbreviations: LogN, LogNormal; ExtremeV, Extreme Value.

Variable	Valid N	% Valid Obs.	Skewness	Kurtosis	Standard Normality Tests	Distribution 1st Similar; Likelihood	Distribution 2nd Similar; Likelihood
TRJ_R00	2123	64.6	1.6	2.8	K–S d = 0.35507. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.69944. $p = 0.00$	LogN10; –3640962	LogN; –3640962
TRJ_R05	1624	49.4	1.8	3.0	K–S d = 0.43852. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.59506. $p = 0.00$	ExtremeV; –4360485	LogN; –2462986
TRJ_R06	2475	75.3	1.3	1.9	K–S d = 0.30496. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.75174. $p = 0.00$	Weibull; –18893110	Normal; –18850110
TRJ_R07	3287	100.0	0.6	0.5	K–S d = 0.12878. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.96351. $p = 0.00$	ExtremeV; –30175610	Normal; –30030220
TRJ_sum_J00_J06	3286	100.0	0.6	0.7	K–S d = 0.05410. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.97683. $p = 0.00$	LogN; –30985510	LogN10; –30985510
TRJ_sum_J12_18	3283	99.9	0.6	0.4	K–S d = 0.08876. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.96812. $p = 0.00$	LogN10; –18148780	LogN; –18148780
TRJ_sum_J20_j22	3151	95.9	1.0	1.6	K–S d = 0.14026. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.91796. $p = 0.00$	LogN; –10771570	LogN10; –10771570
TRJ_sum_J31_J34	2943	89.5	0.6	0.2	K–S d = 0.09412. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.95947. $p = 0.00$	LogN; –18465880	LogN10; –18465880
TRJ_sum_J37_J39	2528	76.9	1.1	1.3	K–S d = 0.18902. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.86093. $p = 0.00$	LogN10; –6469712	LogN; –6469712
TRJ_sum_J40_J42	1062	32.3	2.1	4.8	K–S d = 0.36616. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.66306. $p = 0.00$	ExtremeV; –1781786	Normal; –1747864
TRJ_sum_J43_J44	3141	95.6	1.0	1.4	K–S d = 0.21734. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.88517. $p = 0.00$	LogN; –6702670	LogN10; –6702670
TRJ_sum_J45_J46	3122	95.0	0.7	0.0	K–S d = 0.13202. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro–Wilk W = 0.94005. $p = 0.00$	LogN10; –14354210	LogN; –14354210

TRJ_sum_I 21_I23	3256	99.1	0.7	0.6	K-S d = 0.18745. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.92258. $p = 0.00$	LogN; -9236908	LogN10; -9236908
TRJ_sum_I 63_I64	3267	99.4	0.7	0.4	K-S d = 0.13726. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.94685. $p = 0.00$	LogN10; -9481207	LogN; -9481207
TRJ_sum_I 65_I66	2130	64.8	1.2	1.1	K-S d = 0.23949. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.84043. $p = 0.00$	LogN10; -5104719	LogN; -5104719
TRJ_J11	213	6.5	2.7	10.0	K-S d = 0.46368. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.51370. $p = 0.00$	ExtremeV; -333195	LogN; -332489
TRJ_J30	303	9.2	3.1	9.0	K-S d = 0.53048. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.33165. $p = 0.00$	ExtremeV; -400824	Normal; -394480
TRJ_J47	751	22.8	2.7	6.4	K-S d = 0.52151. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.38298. $p = 0.00$	LogN; -1050949	LogN10; -1050949
TRJ_I20	3110	94.6	0.6	0.2	K-S d = 0.15689. $p < 0.01$ Lilliefors $p < 0.01$ Shapiro-Wilk W = 0.93295. $p = 0.00$	LogN10; -8957948	LogN; -8957948

Table 2. List of significant ($p \leq 0.05$) factors with relevant impact on disease incidence within the Agglomeration of Gdańsk [TRJ], without considering the influence of sea wind (list of abbreviations in Appendix A, detailed model results in Table 5); model F test statistics and p -level.

Disease	%Var	Interactions						F	p
TRJ_R00	7.7%	YYYY * ShipNo	MM * RAIN	NO ₂				5.59	0.00
TRJ_R05	31.2%	RAIN * O ₃	MM * PM _{2.5}	DD * YYYY	MM * TEMP			1.49	0.00
TRJ_R06	30.1%	SO ₂ * O ₃	O ₃ * ShipNo	YYYY * O ₃	DD * MM	YYYY * TEMP	YYYY * WV	1.41	0.00
TRJ_R07	11.1%	SO ₂ * O ₃ NO * ShipNo	YYYY * CO YYYY * WV	ShipNo		NO ₂ * WV	CO * PRES NO _x * HUMID	12.52	0.00
TRJ_sum_J00_J06	56.0%	MM O ₃ * CO CO * BaP	DD * MM MM * PM _{2.5}	MM * YYYY CO ₂ * TEMP	YYYY * SO ₂ TEMP * HUMID	YYYY * O ₃ WV * ShipNo	NO ₂ * O ₃ NO ₂ * BaP	4.52	0.00

Disease	%Var	Interactions						F	p	
TRJ_J11	8.2%	SO ₂ * HUMID	NO2 * BaP					4.96	0.01	
TRJ_sum_J12_18	46.9%	MM	MM * YYYY	NO2 * WV	PM _{2.5} * WV	YYYY*PR ES	PM _{2.5} * BaP	3.28	0.00	
		DD * MM	CO	WV*BaP	TEMP * ShipNo	SO ₂ *Ship No	NO ₂ * HUMID			
		O ₃ * PM _{2.5}								
TRJ_sum_j20_j22	43.9%	CO * PM _{2.5}	YYYY*NO	MM	MM * YYYY	DD * YYYY	CO * BaP	3.70	0.00	
		DD * BaP	RAIN * PM _{2.5}	RAIN *O ₃						
TRJ_J30	18.7%	YYYY * WV	RAIN *TEMP	WV* TEMP				4.39	0.00	
TRJ_sum_J31_J34	10.9%	WV * ShipNo	NO*O3	MM*WV	YYYY* SO ₂	O ₃ *CO	NO ₂ * O ₃	6.86	0.00	
		PM _{2.5} * ShipNo	O ₃ * TEMP	RAIN *PM ₁₀	YYYY * NO					
TRJ_sum_J37_J39	12.1%	CO2	DD * NO * CO ₂	YYYY * PM ₁₀	NO * WV	YYYY * HUMID			4.59	0.00
TRJ_sum_J40_J42	32.9%	YYYY	WV * BaP	NO ₂ * TEMP				37.10	0.00	
TRJ_sum_J43_J44	13.1%	MM	NO ₂ * ShipNo	YYYY * PM10	O ₃ * BaP				2.66	0.00
TRJ_sum_J45_J46	12.2%	CO ₂ * ShipNo	NO ₂ * WV	CO * WV	RAIN * MM	YYYY * CO ²	O ₃ * PM10	6.08	0.00	
		NO ₂	WV	NO ₂ * ShipNo	YYYY * ShipNo	MM * O ₃				
TRJ_J47	6.1%	YYYY * WV						4.14	0.00	
TRJ_I20	7.8%	ShipNo	YYYY * ShipNo	NO _x * WV	CO * CO2	NO ₂ * HUMID	SO ₂ * WV	11.94	0.00	
		YYYY * CO								
TRJ_sum_I21_I23	15.9%	YYYY * HUMID	MM * YYYY	RAIN * MM	NO2 * ShipNo	TEMP * BaP	PM _{2.5} * ShipNo	3.65	0.00	
TRJ_sum_I63_I64	3.9%	CO * ShipNo	YYYY * HUMID	NO * TEMP	PM _{2.5} * TEMP	NO ₂ * O ₃	TEMP * BaP	6.70	0.00	
		TEMP *	CO * HUMID	RAIN * BaP	TEMP *					
TRJ_sum_I65_I66	2.3%	TEMP *	CO * HUMID	RAIN * BaP	TEMP *				8.09	0.00

Disease	%Var	Interactions					F	p
		HUMID			ShipNo			

Table 3. List of factors with relevant impact on the incidence of diseases within the Agglomeration of Gdańsk [TRJ], considering the influence of sea wind (list of abbreviations in Appendix A, detailed model results in Table 6); model F test statistics and *p*-level.

Variables	%Var	Interactions						F	p
TRJ_R00	31.8%	YYYY * NO _x	DD * O ₃	DD * PRES	O ₃ * CO ₂			2.12	0.00
TRJ_R05	N/O								
TRJ_R06	8.2%	YYYY * O ₃	CO * TEMP	RAIN * NO				4.88	0.00
TRJ_R07	7.1%	YYYY * NO ₂	WV * HUMID	YYYY * NO _x				3.29	0.00
TRJ_sum_J00_J06	56.7%	YYYY * PM ₁₀	RAIN * PM ₁₀	MM * PRES	NO ₂ * ShipNo	MM * YYYY	NO ₂ * NO _x	6.38	0.00
		RAIN * BaP	MM * PM ₁₀						
TRJ_J11	N/O								
TRJ_sum_J12_18	49.1%	MM * CO ₂	WV * TEMP	YYYY * BaP	MM * BaP	DD * RAIN	O ₃ * BaP	3.61	0.00
		DD * WV	DD * SO ₂						
TRJ_sum_j20_j22	43.2%	MM	DD * BaP	YYYY * NO _x	YYYY * BaP	ShipNo * BaP	MM * HUMID	5.50	0.00
		NO * O ₃							
TRJ_J30	N/O								
TRJ_sum_J31_J34	9.7%	O ₃ * HUMID	MM * NO	WV * ShipNo	SO ₂ * BaP	CO ₂	NO * NO ₂	3.38	0.00
TRJ_sum_J37_J39	24.1%	RAIN * BaP	YYYY * PRES	HUMID * ShipNo	DD * WV			2.97	0.00
TRJ_sum_J40_J42	79.1%	PM _{2.5} * HUMID	PM ₁₀ * PM _{2.5}	RAIN * PRES * ShipNo	NO _x * HUMID	WV * HUMID	RAIN * TEMP	4.93	0.00
		RAIN * WV	MM * YYYY						
TRJ_sum_J43_J44	9.6%	TEMP	NO _x * WV	RAIN * TEMP				19.17	0.00
TRJ_sum_J45_J46	5.9%	WV * ShipNo	NO ₂ * PRES	PM ₁₀ * PM _{2.5}	PRES	RAIN * PM _{2.5}		6.83	0.00
TRJ_J47	57.1%	YYYY * BaP	DD * BaP	YYYY * NO				2.89	0.00

Variables	%Var	Interactions		F	p
TRJ_I20	2.0%	NO _x * WV	RAIN *TEMP	5.62	0.00
TRJ_sum_I21_I23	17.6%	NO ₂ * BaP	MM * YYYY	1.61	0.00
TRJ_sum_I63_I64	N/O				
TRJ_sum_I65_I66	6.4%	O ₃ * WV	CO ₂ * ShipNo	12.59	0.00

“N/O”: A stable model could not be identified. Source: authors’ own work.

3.1. Identification of Disease Factors

The disease factors for the Agglomeration of Gdańsk were identified in two stages. The first stage was to identify models without singling out sea wind as a factor (full models), i.e., ones which considered all emission sources, both local and maritime. The second stage was to set up models for sea winds only (designation of variable: WSea) to allow the identification of factors attributable to ships entering/leaving the port and moored at berth, including those that continued to emit exhaust gases from their power generators during cargo-handling operations. The principal ingredients of pollution attributable to ships at the port include CO₂, CO, SO_x, NO_x and PM [27]. With the entry into force in 2015 of the Sulphur Directive [28], the use of heavy fuel oils (HFO) was banned across the entire Baltic Sea area for ships without adequate equipment (scrubbers) to purify sulfur emissions. While shipping no longer seems to emit appreciable amounts of SO₂, the other pollutants, especially NO₂ and PM, still continue to seriously pollute urban air within the agglomeration.

With this in mind, a list was drawn up to identify diseases whose incidence within the Agglomeration of Gdańsk is attributable to air pollution generated, among other sources, by the city port. The diseases include abnormalities of heartbeat (R00), cough (R05), abnormalities of breathing (R06), pain in the throat and chest (R07), acute nasopharyngitis, acute sinusitis, acute pharyngitis, acute tonsillitis, acute laryngitis and tracheitis, acute obstructive laryngitis and epiglottitis, acute upper respiratory infections of multiple or unspecified sites (J00–J06), influenza due to unidentified virus (J11), viral pneumonia (J12–J18), acute bronchitis, broncholitis and unspecified acute lower respiratory infection (J20–J22), vasomotor and allergic rhinitis (J30), chronic rhinitis, nasopharyngitis and pharyngitis, sinusitis, nasal polyp and other disorders of the nose and nasal sinuses (J31–J34), chronic laryngitis and laryngotracheitis, diseases of the vocal cords and larynx not elsewhere classified, and other diseases of the upper respiratory tract (J37–J39), bronchitis (J40–J42), emphysema and other chronic obstructive pulmonary diseases (J43–J44), asthma and status asthmaticus (J45–J46), bronchiectasis (J47), angina pectoris (I20), acute myocardial infarction, subsequent myocardial infarction and certain current complications following acute myocardial infarction (I21–I23), cerebral infarction and stroke not specified as haemorrhage or infarction (I63–I64), as well as occlusion and stenosis of precerebral arteries not resulting in cerebral infarction (I65–I66). However, their correlation factor (compare the “%Var” columns in Table 2 and Table 3) ranges widely from 2.0% to 79.1%. Also, separate analyses are required for outcomes obtained for urban pollution not including shipping operations at port and for pollution outcomes including that factor. The details are presented in Table 2 and Table 3.

The most noteworthy three out of the 19 identified diseases are acute severe asthma, chronic obstructive pulmonary disease and pneumonia. Air pollution penetrates into the body by means of the lungs, which act as a protective filter and therefore bear the brunt of infections transmitted by air. The most severe consequences include pneumonia, which is a cause of numerous deaths, acute severe asthma, as well as COPD, a life-threatening condition which exposes the healthcare system in Poland to considerable financial losses. For that reason, the further discussion will focus in detail on these three diseases to explain the correlations identified by stochastic models.

3.1.1. Acute severe asthma [J45–J46]

The applied full models account for 12.2% of variability in incidence rates for bronchial asthma (R²) depending on air pollution. Statistically relevant factors correlating with incidence include:

CO₂ * ShipNo | NO₂ * WV | CO*WV | RAIN * MM | YYYY*CO₂ | O₃ * PM₁₀ | NO₂ | WV | NO₂ * ShipNo | YYYY * ShipNo | MM*O₃

The findings point to a strong influence of annual seasonality with periodical peaks of incidence related to natural trends, variable concentrations of CO₂ and O₃, and changing patterns of ship traffic where causes may include the spread of chemical compounds resulting from loading/unloading operations (CO₂, NO₂).

The findings point to the prominent role of CO₂, O₃ and NO₂. These compounds are powerful on their own (NO₂), as well as in combination with wind (WV). Interestingly, a statistically relevant interaction of O₃ with particulate matter PM₁₀ has been found.

Models for sea wind direction account for approx. 6% of variability in incidence rates for asthma. The following variables have been identified as statistically relevant factors:

WV.Wsea * ShipNo | NO₂.Wsea * PRES.Wsea | PM₁₀.Wsea * PM_{2.5}.Wsea | PRES.Wsea | RAIN.Wsea * PM_{2.5}.Wsea

This is a refinement of the findings explaining the influence of pollutants (NO₂, PM₁₀) attributable to ship traffic, and of PM_{2.5} in conjunction with PM₁₀ and in combination with rain.

3.1.2. Chronic obstructive pulmonary disease (COPD) [J43–J44]

Full models account for 13.1% of variability incidence rates for COPD (cf. Table 2). Statistically relevant factors correlating with incidence include:

MM | TRJ.NO₂ * ShipNo | YYYY*TRJ.PM₁₀ | TRJ.O₃ * TRJ.BaP

The findings show that the factors with the most impact on incidence of COPD within the Tricity area include: NO₂ related to ship traffic, PM₁₀ and interactions between O₃ and BaP.

Another factor with a strong influence on incidence is seasonality. Models for sea wind direction account for approx. 9.6% of the variability. Statistically relevant factors include the following variables:

TEMP.Wsea | NOX.Wsea*WV.Wsea | RAIN.Wsea Y_N*TEMP.Wsea

That is to say, temperature fluctuations and seasonality of incidence as well as NO_x in conjunction with sea wind (WV.Wsea).

3.1.3. Pneumonia [TRJ_sum_J12_18]

Full models account for 46.9% of variability in incidence rates for pneumonia (Table 2). This is among the highest values, pointing to a strong correlation with incidence.

Statistically relevant factors include the following variables:

MM | MM * YYYY | NO₂ * WV | PM_{2.5} * WV | YYYY * PRES | PM_{2.5} * BaP | DD * MM | CO. WV * BaP | TEMP * ShipNo | SO₂ * ShipNo | NO₂ * HUMID | O₃ * PM_{2.5}

The findings show that the leading factors with impact on the incidence of pneumonia within the Tricity area include: NO₂, PM_{2.5}, CO, BaP and SO₂ related to emissions from ships.

In addition to the seasonality (MM.YYYY.DD), incidence is also affected by weather conditions (wind, temperature, humidity). Noteworthy in this regard are interactions between O₃ and PM_{2.5} and between ship traffic and temperature (TEMP * ShipNo).

Models for sea wind direction account for approx. 49% of the variability, a high proportion. Statistically relevant factors include the following variables:

MM * CO₂.Wsea | WV.Wsea * TEMP.Wsea | YYYY * BaP | MM * BaP | DD * RAIN.Wsea Y_N | O₃.Wsea * BaP | DD * WV.Wsea | DD * SO₂.Wsea

These models give a more detailed picture of the situation by pointing to a strong influence of BaP, both periodically (YYYY * BaP) and in conjunction with O₃. Also, previous findings have been confirmed: CO₂ and SO₂ blown in from the sea and ports have a serious impact on incidence.

3.2. Identification of the Financial Costs of Medical Treatment

Treatment costs to medical service providers have been calculated for the 19 diseases identified above on the basis of medical treatment price lists for various types of respiratory diseases supplied by the Military Institute of Medicine. Due consideration has been given to the criterion of relevance to life safety. The calculation covers only three diseases named in section 3.1., items 1–3. This has helped to establish the average cost rates for each of the five cost groups and the amounts refunded by the National Health Fund. The figures are set out in Table 4. Even a cursory analysis has shown a wide disparity between actual costs paid by medical service providers (hospitals) and amounts recovered from the National Health Fund in reimbursement for these services. Funding gaps are widest for pneumonia. The figures presented below may be utilized in the future to conduct a more detailed study of the Polish healthcare system with the aim of closing the gap between medical costs and available refunds. This also shows the scale of expenditure on specific diseases.

Table 4. Financial costs of medical treatment of selected diseases related to air pollution within the Agglomeration of Gdańsk in 2018 (1 euro = PLN 4.3).

Disease	Acute Severe Bronchial Asthma J45–J46	Chronic Obstructive Pulmonary Disease (COPD) J43–J44	Pneumonia J12–J18
Avg. length of hospitalization	8.64 days	6.4 days	13.41 days
Avg. Polish National Health Fund (NFZ) refund	PLN 4179.36	PLN 2243.47	PLN 3191.06
Avg. medical care cost	PLN 4076.19	PLN 2811.82	PLN 6239.33
Avg. daily hospitalization cost	PLN 1259.90	PLN 899.31	PLN 1935.67
Avg. diagnostic cost	PLN 597.82	PLN 401.33	PLN 1312.11
Avg. medication cost	PLN 255.86	PLN 99.84	PLN 929.31
Avg. consultation cost	PLN 36.00	PLN 19.20	PLN 69.88
Total of average costs	PLN 6225.77	PLN 4231.50	PLN 10,486.30
Average financial result	PLN -2046.41	PLN -1988.04	PLN -7295.25
Number of incidents	1318	851	2100
Total cost of treatment	PLN 8,205,563.86	PLN 3,601,006.50	PLN 22,021,230.00
Total cost refunded	PLN 5,508,396.48	PLN 1,909,192.97	PLN 6,701,226.00
Funding gap	PLN -2,695,167.38	PLN -1,691,813.53	PLN -15,320,004.00

4. Discussion

4.1. Regarding the Health and Environmental Component

The research presented in this paper is a preliminary pilot study bringing together, for the first time, a vast collection of over 14 million records on medical services with environmental data. The study has clearly shown a cause-and-effect relationship between air pollution generated by industrial operations, ports and shipping, and disease incidence rates within the Agglomeration of Gdańsk. However, the results are far from final. More research is necessary to study other agglomerations and cities for a more accurate understanding of relations between the impact factors, the agglomeration's location and the associated pollution levels. Such further research will verify the accuracy of the GRM model.

Another area of concern relates to the coverage of data collected by public health institutions (mainly the National Health Fund—NFZ) and environmental monitoring bodies. Record-keeping should preferably evolve towards a detailed description of medical services to allow the identification of the gender and age of patients, length of medical leave due to a particular disease, and type of medical services provided. As for environmental data, it would be desirable to increase the number of atmospheric measurement stations to allow the investigation of the spatial distribution of incidence of diseases attributable to air pollution. It would also be useful to map the location of the major emitters of pollutants (e.g., refineries, garbage incineration plants and timber mills).

The areas for future research into the impact of pollution on diseases include both methodological and factual aspects of the problem. Further work in these areas should identify pollutants with the greatest impact on the incidence of various diseases in society and, by extension, also set up a framework to combat pollution. Such a framework should indicate action to target those sources of pollution whose elimination will be the most beneficial.

4.2. Regarding the Economic Component

Within the economic section of the paper, some concerns may arise as to the calculated average costs of treatment of selected diseases. However, without listing these costs separately by specific types of medical services (hospitalization, medication, diagnostics, etc.), it would be impossible to accurately identify which financial costs are incurred by urban air pollution. That is why it is necessary to keep records listing the costs incurred by a medical service provider in offering specific

medical procedures. Such records should preferably indicate the amount of National Health Fund (NFZ) refunds provided under contract with a specific medical service provider. Such a step will paint a more accurate picture of the Polish healthcare system's funding shortfall.

Also, establishing a correlation between incidence rates for diseases resulting from air pollution with their treatment costs would allow for a much more adequate framework to be set up to support the process of treatment and to match refunds with service provider needs. In effect, this would considerably reduce the disparities between financial expectations and actual cash flows. It would therefore be necessary to examine in more detail the issue of shortfall in the funding.

With respect to further detailed research, it would be desirable to analyze the cost variability over time of the treatment of diseases related to ship traffic within ports so as to identify the economic impact of ports on the health condition of populations residing in port cities. It would be especially interesting to look at cost variation in the Baltic Sea Region in response to the 2015 Sulphur Directive.

A further step with interesting implications for social economics would be to extend the calculations to the external costs of diseases. These costs would have to be correlated with average salaries, the resulting lost earnings, costs to employers, who—according to Polish law—are obliged to pay sickness benefits for the first 33 days of sick leave, and costs to the Polish Social Insurance Company (ZUS), which is obliged to provide sick pay from the 34th day onwards. This would set the stage for even more in-depth research to identify the full indirect costs of diseases and total economic costs of urban air pollution. This would have the added benefit of elaborating in-depth cost optimization models for medical treatment, while also identifying extreme deviations from average values, the structure of medical treatment costs, and how these figures differ across various medical service recipients.

5. Conclusions

This study is a pilot project, as the identified models require in-depth analysis and in-depth interpretation in order to fully understand the impact on every disease. It is also necessary to carry out a comparative study of the findings with their counterparts for other Polish cities such as Cracow and Warsaw. Whatever findings are now available represent high value as they reveal, for the first time in Poland, some significant impact factors and their interactions that contribute to selected diseases in the long term. However, further research is necessary to fully understand the statistical importance of disease factors depending on the region and degree of local pollution. This would allow for a full estimate of costs to urban populations as a result of industrial and urban air pollution.

Appendix A

Reference automatic measurement results (1 hour; $\mu\text{g}/\text{m}^3$) aggregated (averages) to a day in models	
Variable	Description
TRJ.SO ₂ [SO ₂ in tables]	SO ₂ [$\mu\text{g}/\text{m}^3$]
TRJ.NO	NO [$\mu\text{g}/\text{m}^3$]
TRJ.NO ₂ [NO ₂ in tables]	NO ₂ [$\mu\text{g}/\text{m}^3$]
TRJ.NO _x [NO _x in tables]	NO _x [$\mu\text{g}/\text{m}^3$]
TRJ.O ₃ [O ₃ in tables]	O ₃ [$\mu\text{g}/\text{m}^3$]
TRJ.CO	CO [$\mu\text{g}/\text{m}^3$]
TRJ.CO ₂ [CO ₂ in tables]	CO ₂ [$\mu\text{g}/\text{m}^3$]
TRJ.PM ₁₀ [PM ₁₀ in tables]	PM ₁₀ [$\mu\text{g}/\text{m}^3$]
TRJ.PM _{2.5} [PM _{2.5} in tables]	PM _{2.5} [$\mu\text{g}/\text{m}^3$]
TRJ.BaP	Benzapirene [$\mu\text{g}/\text{m}^3$]
TRJ.PRES	Atmospheric pressure [hPa]
TRJ.WV	Wind speed [m/s]
TRJ.TEMP	Temperature [degrees Celsius]
TRJ.HUMID	Humidity [%]
TRJ.RAIN	Rainfall [mm]
TRJ.SO ₂ .Wsea	SO ₂ [$\mu\text{g}/\text{m}^3$]
TRJ.NO.Wsea	NO [$\mu\text{g}/\text{m}^3$]
TRJ.NO ₂ .Wsea	NO ₂ [$\mu\text{g}/\text{m}^3$]

TRJ.NOx.Wsea	NOx [$\mu\text{g}/\text{m}^3$]
TRJ.O3.Wsea	O ₃ [$\mu\text{g}/\text{m}^3$]
TRJ.CO.Wsea	CO [$\mu\text{g}/\text{m}^3$]
TRJ.CO ₂ .Wsea	CO ₂ [$\mu\text{g}/\text{m}^3$]
TRJ.PM ₁₀ .Wsea	PM ₁₀ [$\mu\text{g}/\text{m}^3$]
TRJ.PM _{2.5} .Wsea	PM _{2.5} [$\mu\text{g}/\text{m}^3$]
TRJ.PRES.Wsea	Atmospheric pressure [hPa]
TRJ.WV.Wsea	Wind speed [m/s]
TRJ.TEMP.Wsea	Temperature [degrees Celsius]
TRJ.HUMID.Wsea	Humidity [%]
TRJ.RAIN.Wsea	Rainfall [mm]
Number of provisions aggregated (sum) to a day in models	
ICD10 Code	Description
TRJ_I20	Coronary artery disease
TRJ_I21	Acute heart attack
TRJ_I22	Another heart attack (reinfarction)
TRJ_I23	Complications occurring during acute myocardial infarction
TRJ_I24	Other acute forms of ischemic heart disease
TRJ_I25	Chronic ischemic heart disease
TRJ_I46	Cardiac arrest
TRJ_I47	Paroxysmal tachycardia
TRJ_I48	Atrial fibrillation
TRJ_I49	Other cardiac arrhythmia
TRJ_I50	Heart failure
TRJ_I51	Heart disease not precisely defined and complications of heart disease
TRJ_I52	Other cardiac dysfunction in diseases classified elsewhere
TRJ_I63	Cerebral infarction
TRJ_I64	Stroke, not defined as hemorrhagic or infarcted
TRJ_I65	Blockage and narrowing of the pre-cerebral arteries that do not cause cerebral infarction
TRJ_I66	Blockage and narrowing of the cerebral arteries that do not cause cerebral infarction
TRJ_I67	Other cerebrovascular diseases
TRJ_I68	Cerebrovascular disorders in diseases occurring elsewhere
TRJ_I69	Consequences of cerebrovascular diseases
TRJ_R00	Heart disorders
TRJ_R05	Cough
TRJ_R06	Breathing disorders
TRJ_R07	Sore throat and chest
TRJ_J00	Acute inflammation of the nose and throat (common cold)
TRJ_J01	Acute sinusitis
TRJ_J02	Acute pharyngitis
TRJ_J03	Acute tonsillitis
TRJ_J04	Acute laryngotracheitis
TRJ_J05	Acute obstructive laryngitis and epiglottitis
TRJ_J06	Acute upper respiratory tract infection with multiple or unspecified localization
TRJ_J11	Flu caused by an unidentified virus
TRJ_J12	Viral pneumonia, not elsewhere classified
TRJ_J13	Streptococcal pneumonia (<i>Streptococcus pneumoniae</i>)
TRJ_J14	Pneumonia caused by influenza bacillus (<i>Haemophilus influenzae</i>)
TRJ_J15	Bacterial pneumonia, not elsewhere classified
TRJ_J16	Pneumonia caused by other microorganisms not elsewhere classified
TRJ_J17	Pneumonia in diseases classified elsewhere
TRJ_J18	Pneumonia caused by an unspecified microorganism
TRJ_J20	Acute bronchitis
TRJ_J21	Acute bronchiolitis
TRJ_J22	Unspecified acute lower respiratory infection
TRJ_J30	Angioedema and allergic rhinitis
TRJ_J31	Chronic nasopharyngitis
TRJ_J32	Chronic sinusitis

TRJ_J33	Nasal polyp
TRJ_J34	Other diseases of the nose and paranasal sinuses
TRJ_J35	Chronic tonsil and pharyngeal tonsil diseases
TRJ_J36	Peritonsillar abscess
TRJ_J37	Chronic laryngitis and tracheitis
TRJ_J38	Inflammation of the vocal cords and larynx, not elsewhere classified
TRJ_J39	Other diseases of the upper respiratory tract
TRJ_J40	Bronchitis not defined as acute or chronic
TRJ_J41	Chronic, simple, and mucopurulent bronchitis
TRJ_J42	Unspecified chronic bronchitis
TRJ_J43	Emphysema
TRJ_J44	Other chronic obstructive pulmonary disease
TRJ_J45	Bronchial asthma
TRJ_J46	Status asthmaticus
TRJ_J47	Bronchiectasis
Time variables (binary in models) and ship numbers	
Variable	Description
DD	Day
MM	Month
YYYY	Year
ShipNo	Number of ships entering the port of Gdańsk
Abbreviations:	
TRJ	Tricity Agglomeration (Gdańsk)
AMxx	Designation of ARMAAG measuring stations
Wsea	Measurement results for winds blowing from the sea

Figure A1. List of all variables used for cause-and-effect models.

Appendix B

Due to the volume (several thousand verified factor interactions), the final results of significance tests will be presented synthetically.

The GRM model identification process took place in three main general stages:

In the first stage, models without interaction were tested, and the significance of each parameter was tested using standard tests based on the Student's *t* distribution, the significance of the model based on Fisher's distribution (*F* test), and the degree of variation explanation by the model (multiple *R*, *R*² and corrected *R*²).

Second, the next step was to identify, in addition, all statistically significant interactions of independent variables to the second degree. For this purpose, two parallel iterative procedures for model building were used: forward stepwise and best subset with the *R*² criterion. As a result of comparing the results of both iterative procedures, independent variables significantly related to the dependent variable (selected cases of diseases) were selected.

The final stage of model identification was to build the model only with variables statistically significantly associated with the dependent variable. If there was more than one such model, the one for which *R*² was higher was chosen and the assumptions of its applicability were examined, i.e., the normality of the random component within the level of each factor, and each interaction, was assessed separately. Due to the large volume of results for presentation, a table was built with the names of factors significantly related to the dependent variable (according to Appendix A).

In some cases, it was necessary to repeatedly test various factor systems and their interactions, despite the use of iterative procedures. The final model was a model with the least number of factors at the highest or similar level of explained variance to more complex models.

In the intermediate identification stages, selected additional tools were used: Pareto charts, Ljung Box Pierce Q tests (in model stationary testing), and another visualization tool.

Appendix B presents the final working result (print from the Statistica system, with manual corrections) tables of model estimations, results of significance tests for each factor and interaction in the models, as well as selected intermediate stages of the process of identifying selected variables.

Due to the size of the result sets (in the order of several thousand pages), it is not possible to present all the detailed result sets.

Sample, selected results of the model identification process for TRJ_sum_J00_J06:

Univariate Tests of Significance for TRJ_sum_J00_J06 (#TRJ DD2010_2018 in NFZ main 2010 WORK EN v093.stw)						
TRJ_sum_J00_J06 Sigma-Restricted Parameterization						
Effective Hypothesis Decomposition; Std. Error of Estimate: 360,2027						
Include Condition: YYYY ≥ 2010 AND YYYY ≤ 2018						
Model Without Interactions:	Effect	Sum of Squares (SS)	df; degr. freedom	Mean Squares (MS)	F	p
	Intercept	694,149	1	694,149	5.35006	0.020824
	TRJ.SO ₂	717,53	1	717,53	0.55303	0.457171
	TRJ.NO	574,957	1	574,957	4.43141	0.035410
	TRJ.NO ₂	478,351	1	478,351	3.68683	0.054988
	TRJ.NO _x	599,354	1	599,354	4.61944	0.031733
	TRJ.O ₃	11,901	1	11,901	0.09172	0.762030
	TRJ.CO	1,013,120	1	1,013,120	7.80848	0.005251
	TRJ.CO ₂	4433	1	4433	0.03417	0.853365
	TRJ.PM ₁₀	470,499	1	470,499	3.62631	0.057019
	TRJ.PM _{2.5}	2297590	1	2,297,590	17.70837	0.000027
	TRJ.PRES	198,225	1	198,225	1.52779	0.216592
	TRJ.WV	1,978,574	1	1,978,574	15.24960	0.000097
	TRJ.TEMP	1,170,582	1	1,170,582	9.02210	0.002701
	TRJ.HUMID	427,233	1	427,233	3.29284	0.069735
	ShipNo	684,749	1	684,749	5.27762	0.021706
	TRJ.BaP	43,494	1	43,494	0.33523	0.562664
	DD	2,309,906	30	76,997	0.59344	0.960926
	MM	43,002,543	11	3,909,322	30.13058	0.000000
	YYYY	13,655,564	7	1,950,795	15.03549	0.000000
	TRJ.RAIN Y_N	78,129	1	78,129	0.60217	0.437844
	Error	255,210,364	1967	129,746		

Dependent Variable Test of SS Whole Model vs. SS Residual (#TRJ DD2010_2018 in NFZ main 2010 WORK EN v093.stw) Include Condition: YYYY ≥ 2010 AND YYYY ≤ 2018

Effect	Multiple R	Multiple R ²	Adjusted R ²	SS	df	MS	SS	df	MS	F	p
TRJ_sum_J00_J06	0.60	0.36	0.34	141376559	64	2,209,009	255,210,364	1967	129,746.0	17.02564	0.00

Summary of Stepwise Regression; Variable: TRJ_sum_J00_J06 (#TRJ DD2010_2018 in NFZ main 2010 WORK EN v093.stw)								
Forward Stepwise P to Enter: 0.05; P to remove: 0.05								
Include Condition: YYYY ≥ 2010 AND YYYY ≤ 2018								
Effect	Steps	Degr. Of Freedom	F to Remove	P to Remove	F to Enter	P to Enter	Effect Status	
MM	Step Number 24	10	12.008	0.000			In	
TRJ.CO ₂ * TRJ.TEMP		1	14.356	0.000			In	

DD * MM	330	1.269	0.002	In
TRJ.NO ₂ * TRJ.O ₃	1	28.527	0.000	In
TRJ.WV * ShipNo	1	17.907	0.000	In
YYYY * TRJ.O ₃	7	5.174	0.000	In
MM * YYYY	77	3.687	0.000	In
TRJ.O ₃ * TRJ.CO	1	29.562	0.000	In
MM * TRJ.PM _{2.5}	11	2.702	0.002	In
TRJ.NO ₂ * TRJ.BaP	1	12.433	0.000	In
TRJ.CO * TRJ.BaP	1	6.079	0.014	In
YYYY * TRJ.SO ₂	7	2.324	0.023	In
TRJ.TEMP *	1	4.637	0.031	In
TRJ.HUMID				

Dependent Variable: Test of SS Whole Model vs. SS Residual (#TRJ DD2010_2018 in NFZ main 2010 WORK EN v093.stw)
Include Condition: YYYY ≥ 2010 AND YYYY ≤ 2018

Effect	Multiple R	Multiple R ²	Adjusted R ²	SS	df	MS	SS	df	MS	F	p
TRJ_sum_J00_J06	0.75	0.56	0.44	22,209,729	446	497,976	174,489,628	1585	110,088	4.52	0.00

Table 5. A list of significant ($p \leq 0.05$) factors with relevant impact on disease incidence within the Agglomeration of Gdańsk [TRJ], without considering the influence of sea wind (list of abbreviations in Appendix A); df, SS (Sum of squares), MS (Mean squares), F statistics and p -level of factors and interactions.

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
TRJ_R00	Intercept	1	7,646,826	7,646,826	832.70	0.00
	YYYY * ShipNo	7	665,979	95,140	10.36	0.00
	MM * TRJ.RAIN Y_N	11	293,390	26,672	2.90	0.00
	TRJ.NO ₂	1	46,917	46,917	5.11	0.02
	Error	1276	11,717,736	9183		
	Total	1295	12,693,180			
	Total	1295	12,693,180			
TRJ_R05	Intercept	1	84,590,65	8,459,065	1605.07	0.00
	TRJ.RAIN Y_N * TRJ.O ₃	1	34,080	34,080	6.47	0.01
	MM * TRJ.PM _{2.5}	11	135,951	12,359	2.35	0.01
	YYYY * DD	210	1,380,290	6,573	1.25	0.02
	MM * TRJ.TEMP	11	224,528	20,412	3.87	0.00
	Error	765	4,031,716	5270		
	Total	998	5,857,466			
TRJ_R06	Intercept	1	6,811,330	6,811,330	629.80	0.00
	TRJ.SO ₂ * TRJ.O ₃	1	130,206	130,206	12.04	0.00
	TRJ.O ₃ * ShipNo	1	66,003	66,003	6.10	0.01
	YYYY * TRJ.O ₃	7	259,244	37,035	3.42	0.00
	DD * MM	330	4,285,668	12,987	1.20	0.02
	YYYY * TRJ.TEMP	7	211,663	30,238	2.80	0.01
	YYYY * TRJ.WV	7	192,013	27,430	2.54	0.01
	Error	1162	12,567,202	10,815		
	Total	1515	17,969,271			
TRJ_R07	Intercept	1	36,224,059	36,224,059	650.03	0.00
	TRJ.SO ₂ * TRJ.O ₃	1	1,124,489	1,124,489	20.18	0.00
	YYYY * TRJ.CO	7	1,944,100	277,729	4.98	0.00
	ShipNo	1	682,159	682,159	12.24	0.00
	TRJ.NO ₂ * TRJ.WV	1	1,170,553	1,170,553	21.01	0.00
	TRJ.CO * TRJ.PRES	1	1,028,956	1,028,956	18.46	0.00

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
	TRJ.NO _x * TRJ.HUMID	1	839,760	839,760	15.07	0.00
	TRJ.NO * ShipNo	1	219,653	219,653	3.94	0.05
	YYYY * TRJ.WV	7	810,664	115,809	2.08	0.04
	Error	2011	112,066,208	55,727		
	Total	2031	126,018,502			
TRJ_sum_J00_J06	Intercept	0				
	MM	7	13,252,869	1,893,267	17.20	0.00
	DD * MM	326	46,207,886	141,742	1.29	0.00
	MM * YYYY	77	31,335,749	406,958	3.70	0.00
	YYYY * TRJ.SO ₂	7	1,795,535	256,505	2.33	0.02
	YYYY * TRJ.O ₃	7	3,997,314	571,045	5.19	0.00
	TRJ.NO ₂ * TRJ.O ₃	1	3,148,433	3,148,433	28.60	0.00
	TRJ.O ₃ * TRJ.CO	1	3,262,647	3,262,647	29.64	0.00
	MM * TRJ.PM _{2.5}	11	3,280,922	298,266	2.71	0.00
	TRJ.CO ₂ * TRJ.TEMP	1	1,584,436	1,584,436	14.39	0.00
	TRJ.TEMP * TRJ.HUMID	1	511,762	511,762	4.65	0.03
	TRJ.WV * ShipNo	1	1,976,330	1,976,330	17.95	0.00
	TRJ.NO ₂ * TRJ.BaP	1	1,372,225	1,372,225	12.46	0.00
	TRJ.CO * TRJ.BaP	1	670,972	670,972	6.09	0.01
	Error	1585	174,489,628	110,088		
	Total	2031	396,586,924			
TRJ_J11	Intercept	1	1,522,477	1,522,477	318.84	0.00
	TRJ.SO ₂ * TRJ.HUMID	1	27,526	27,526	5.76	0.02
	TRJ.NO ₂ * TRJ.BaP	1	47,119	47,119	9.87	0.00
	Error	111	530,026	4775		
	Total	113	577,382			
TRJ_sum_J12_18	Intercept	0				
	MM	7	8,898,402	1,271,200	24.06	0.00
	MM * YYYY	77	8,142,020	105,741	2.00	0.00
	TRJ.NO ₂ * TRJ.WV	1	1,203,496	1,203,496	22.78	0.00
	TRJ.PM _{2.5} * TRJ.WV	1	224,229	224,229	4.24	0.04
	YYYY * TRJ.PRES	7	1,510,085	215,726	4.08	0.00
	TRJ.PM _{2.5} * TRJ.BaP	1	1,488,907	1,488,907	28.18	0.00
	DD * MM	326	23,524,095	72,160	1.37	0.00
	TRJ.CO	1	1,257,310	1,257,310	23.80	0.00
	TRJ.WV * TRJ.BaP	1	799,585	799,585	15.13	0.00
	TRJ.TEMP * ShipNo	1	631,362	631,362	11.95	0.00
	TRJ.SO ₂ * ShipNo	1	487,546	487,546	9.23	0.00
	TRJ.NO ₂ * TRJ.HUMID	1	558,340	558,340	10.57	0.00
	TRJ.O ₃ * TRJ.PM _{2.5}	1	256,889	256,889	4.86	0.03
	Error	1598	84,426,599	52,833		
	Total	2028	158,882,411			
TRJ_sum_j20_j22	Intercept	1	73,398,579	73,398,579	2338.56	0.00
	TRJ.CO * TRJ.PM _{2.5}	1	349,231	349,231	11.13	0.00
	YYYY * TRJ.NO	7	2089622	298,517	9.51	0.00
	MM	11	9471,001	861,000	27.43	0.00
	MM * YYYY	77	6,273,029	81,468	2.60	0.00
	DD * YYYY	210	8,470,130	40,334	1.29	0.01
	TRJ.CO * TRJ.BaP	1	239,633	239,633	7.63	0.01
	DD * TRJ.BaP	30	1,552,638	51,755	1.65	0.02
	TRJ.RAIN Y_N * TRJ.PM _{2.5}	1	261,201	261,201	8.32	0.00
	TRJ.RAIN Y_N * TRJ.O ₃	1	136,106	136,106	4.34	0.04
	Error	1603	50,312,033	31,386		
	Total	1942	89,639,560			
TRJ_J30	Intercept	1	1,009,646	1,009,646	626.11	0.00
	YYYY * TRJ.WV	7	28,776	4111	2.55	0.02

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
	TRJ.RAIN Y_N * TRJ.TEMP	1	17,369	17,369	10.77	0.00
	TRJ.WV * TRJ.TEMP	1	25,063	25,063	15.54	0.00
	Error	172	277,363	1613		
	Total	181	341,021			
TRJ_sum_J31_J34	Intercept	1	43,460,572	43,460,572	287.63	0.00
	TRJ.WV * ShipNo	1	7,373,160	7,373,160	48.80	0.00
	TRJ.NO * TRJ.O ₃	1	1,593,126	1,593,126	10.54	0.00
	MM * TRJ.WV	11	10,416,502	946,955	6.27	0.00
	YYYY * TRJ.SO ₂	7	7,325,120	1,046,446	6.93	0.00
	TRJ.O ₃ * TRJ.CO	1	3,698,471	3,698,471	24.48	0.00
	TRJ.NO ₂ * TRJ.O ₃	1	4,450,889	4,450,889	29.46	0.00
	TRJ.PM _{2.5} * ShipNo	1	2,654,259	2,654,259	17.57	0.00
	TRJ.O ₃ * TRJ.TEMP	1	1,380,829	1,380,829	9.14	0.00
	TRJ.RAIN Y_N * TRJ.PM ₁₀	1	1,279,038	1,279,038	8.46	0.00
	YYYY * TRJ.NO	7	3,074,650	439,236	2.91	0.01
	Error	1792	270,769,691	151,099		
	Total	1824	303,957,358			
TRJ_sum_J37_J39	Intercept	1	1,014,834	1,014,834	39.72	0.00
	TRJ.CO ₂	1	281,741	281,741	11.03	0.00
	DD * TRJ.NO * TRJ.CO ₂	30	1,222,090	40,736	1.59	0.02
	YYYY * TRJ.PM ₁₀	7	917,807	131,115	5.13	0.00
	TRJ.NO * TRJ.WV	1	369,943	369,943	14.48	0.00
	YYYY * TRJ.HUMID	7	1,757,588	251,084	9.83	0.00
	Error	1538	39,294,057	25,549		
	Total	1584	44,692,024			
TRJ_sum_J40_J42	Intercept	1	8,433,729	8,433,729	621.43	0.00
	YYYY	7	4,505,589	643,656	47.43	0.00
	TRJ.WV * TRJ.BaP	1	188,744	188,744	13.91	0.00
	TRJ.NO ₂ * TRJ.TEMP	1	51,288	51,288	3.78	0.05
	Error	680	9,228,606	13,571		
	Total	689	13,760,572			
TRJ_sum_J43_J44	Intercept	1	13,123,606	13,123,606	991.77	0.00
	MM	11	1,001,725	91,066	6.88	0.00
	TRJ.NO ₂ * ShipNo	1	240,792	240,792	18.20	0.00
	YYYY * TRJ.PM ₁₀	7	345,399	49,343	3.73	0.00
	TRJ.O ₃ * TRJ.BaP	1	75,809	75,809	5.73	0.02
	MM * YYYY	77	1,390,801	18,062	1.37	0.02
	YYYY * TRJ.BaP	7	193,117	27,588	2.08	0.04
	Error	1837	24,308,025	13,232		
	Total	1941	27,970,842			
TRJ_sum_J45_J46	TRJ.CO ₂ * ShipNo	1	2,072,385	2,072,385	22.20	0.00
	TRJ.NO ₂ * TRJ.WV	1	1,235,310	1,235,310	13.23	0.00
	TRJ.CO * TRJ.WV	1	5,157,947	5,157,947	55.26	0.00
	TRJ.RAIN Y_N * MM	11	2,008,318	182,574	1.96	0.03
	YYYY * TRJ.CO ₂	7	1,659,522	237,075	2.54	0.01
	TRJ.O ₃ * TRJ.PM ₁₀	1	1,366,168	1,366,168	14.64	0.00
	TRJ.NO ₂	1	1,248,405	1,248,405	13.37	0.00
	TRJ.WV	1	3,152,965	3,152,965	33.78	0.00
	TRJ.NO ₂ * ShipNo	1	450,728	450,728	4.83	0.03
	YYYY * ShipNo	7	1,442,239	206,034	2.21	0.03
	MM * TRJ.O ₃	11	2,159,772	196,343	2.10	0.02
	Error					
TRJ_J47	Intercept	1	10,447,410	10,447,410	4522.40	0.00
	YYYY * TRJ.WV	7	66,925	9561	4.14	0.00
	Error	443	1,023,395	2310		
	Total	450	1,090,320			
TRJ_I20	Intercept	1	162,711,56	16,271,156	595.84	0.00

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
	ShipNo	1	896,973	896,973	32.85	0.00
	YYYY * ShipNo	7	1,367,431	195,347	7.15	0.00
	TRJ.NO _x * TRJ.WV	1	1,119,542	1,119,542	41.00	0.00
	TRJ.CO * TRJ.CO ₂	1	1,574,286	1,574,286	57.65	0.00
	TRJ.NO ₂ * TRJ.HUMID	1	558,962	558,962	20.47	0.00
	TRJ.WV * TRJ.SO ₂	1	309,655	309,655	11.34	0.00
	YYYY * TRJ.CO	7	580,328	82,904	3.04	0.00
	Error	2688	73,403,890	27,308		
	Total	2707	79,599,759			
TRJ_sum_I21_I23	Intercept	1	2,9781,054	29,781,054	1496.50	0.00
	YYYY * TRJ.HUMID	7	2,697,929	385,418	19.37	0.00
	MM * YYYY	77	3,149,772	40,906	2.06	0.00
	TRJ.RAIN Y_N * MM	11	674,651	61,332	3.08	0.00
	TRJ.NO ₂ * ShipNo	1	213,448	213,448	10.73	0.00
	TRJ.TEMP * TRJ.BaP	1	182,901	182,901	9.19	0.00
	TRJ.PM _{2.5} * ShipNo	1	154,359	154,359	7.76	0.01
	TRJ.NO _x * TRJ.WV	1	72,954	72,954	3.67	0.06
	Error	1914	38,089,533	19,900		
	Total	2013	45,278,017			
TRJ_sum_I63_I64	Intercept	1	13,522,063	13,522,063	640.07	0.00
	ShipNo * TRJ.CO ₂	1	152,596	152,596	7.22	0.01
	YYYY * TRJ.HUMID	7	1,247,543	178,220	8.44	0.00
	TRJ.NO * TRJ.TEMP	1	148,988	148,988	7.05	0.01
	TRJ.TEMP * TRJ.PM _{2.5}	1	195,598	195,598	9.26	0.00
	TRJ.NO ₂ * TRJ.O ₃	1	148,740	148,740	7.04	0.01
	TRJ.TEMP * TRJ.BaP	1	86,417	86,417	4.09	0.04
	Error	2009	42,441,843	21,126		
	Total	2021	44,141,351			
TRJ_sum_I65_I66	Intercept	1	13,410,177	13,410,177	520.46	0.00
	TRJ.TEMP * TRJ.HUMID	1	586,694	586,694	22.77	0.00
	TRJ.CO * TRJ.HUMID	1	210,584	210,584	8.17	0.00
	TRJ.RAIN Y_N * TRJ.BaP	1	158,941	158,941	6.17	0.01
	TRJ.TEMP * ShipNo	1	146,044	146,044	5.67	0.02
	Error	1348	34,732,479	25,766		
	Total	1352	35,566,024			

Table 6. A list of significant ($p \leq 0.05$) factors with relevant impact on disease incidence within the Agglomeration of Gdańsk [TRJ], considering the influence of sea wind (.Wsea; list of abbreviations in Appendix A); df, SS (Sum of squares), MS (Mean squares), F statistics and p -level of factors and interactions.

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
TRJ_R00	Intercept	1	1027,578	1027,578	123.75	0.00
	YYYY * TRJ.NO _x .Wsea	6	249,503	41,584	5.01	0.00
	DD * TRJ.O ₃ .Wsea	30	447,800	14,927	1.80	0.01
	DD * TRJ.PRES.Wsea	30	416,879	13,896	1.67	0.02
	TRJ.O ₃ .Wsea * TRJ.CO ₂ .Wsea	1	40,248	40,248	4.85	0.03
	Error	305	2,532,676	8304		
	Total	372	3,711,880			

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
TRJ_R06	Intercept	1	336,1789	3,361,789	311.08	0.00
	YYYY * TRJ.O ₃ .Wsea	6	273,671	45,612	4.22	0.00
	TRJ.CO ₂ .Wsea * TRJ.TEMP.Wsea	1	67,861	67,861	6.28	0.01
	TRJ.RAIN.Wsea Y _N * TRJ.NO _x .Wsea	1	56,887	56,887	5.26	0.02
	Error	438	4,733,386	10,807		
	Total	446	5155352			
TRJ_R07	Intercept	1	43,369,106	43,369,106	802.24	0.00
	YYYY * TRJ.NO ₂ .Wsea	6	840,766	140,128	2.59	0.02
	TRJ.WV.Wsea * TRJ.HUMID.Wsea	1	334,803	334,803	6.19	0.01
	YYYY * TRJ.NO _x .Wsea	6	734,970	122,495	2.27	0.04
	Error	557	30,111,515	54,060		
	Total	570	32,426,388			
TRJ_sum_J00_J06	Intercept	0				
	YYYY * TRJ.PM ₁₀ .Wsea	6	2082,903	347,150	3.25	0.00
	TRJ.RAIN.Wsea Y _N * TRJ.PM ₁₀ .Wsea	1	896,758	896,758	8.40	0.00
	MM * TRJ.PRES.Wsea	11	6,211,321	564,666	5.29	0.00
	TRJ.NO ₂ .Wsea * ShipNo	1	2,757,706	2757,706	25.83	0.00
	MM * YYYY	65	20,041,562	308,332	2.89	0.00
	TRJ.NO ₂ .Wsea * TRJ.NO _x .Wsea	1	1,923,023	1,923,023	18.01	0.00
	TRJ.RAIN.Wsea Y _N * TRJ.BaP	1	2,934,133	2,934,133	27.48	0.00
	MM * TRJ.PM ₁₀ .Wsea	11	3,983,317	362,120	3.39	0.00
	Error	473	50,506,841	106,780		
	Total	570	116,563,428			
TRJ_sum_J12_18	Intercept	1	15,108,160	15,108,160	306.10	0.00
	MM * TRJ.CO ₂ .Wsea	11	4,726,886	429,717	8.71	0.00
	TRJ.WV.Wsea * TRJ.TEMP.Wsea	1	344,188	344,188	6.97	0.01
	YYYY * TRJ.BaP	6	1,420,069	236,678	4.80	0.00
	MM * TRJ.BaP	11	2,099,516	190,865	3.87	0.00
	DD * TRJ.RAIN.Wsea Y _N	30	2,484,983	82,833	1.68	0.02
	TRJ.O ₃ .Wsea * TRJ.BaP	1	344,452	344,452	6.98	0.01
	DD * TRJ.WV.Wsea	30	2,726,457	90,882	1.84	0.00
	DD * TRJ.SO ₂ .Wsea	30	2,508,048	83,602	1.69	0.01
	Error	449	22,160,910	49,356		
TRJ_sum_j20_j22	Intercept	1	9,393,842	9,393,842	324.88	0.00
	MM	11	899,808	81,801	2.83	0.00
	DD * TRJ.BaP	30	2,313,075	77,102	2.67	0.00
	YYYY * TRJ.NO _x .Wsea	6	847,589	141,265	4.89	0.00
	YYYY * TRJ.BaP	6	642,652	107,109	3.70	0.00
	ShipNo * TRJ.BaP	1	223,510	223,510	7.73	0.01
	MM * TRJ.HUMID.Wsea	11	752,869	68,443	2.37	0.01
	TRJ.NO ₂ .Wsea * TRJ.O ₃ .Wsea	1	190,980	190,980	6.60	0.01
	Error	477	13,792,427	28,915		
	Total	543	24,280,009			
TRJ_sum_J31_J34	Intercept	1	2,283,178	2,283,178	15.24	0.00
	TRJ.O ₃ .Wsea * TRJ.HUMID.Wsea	1	2,658,824	2,658,824	17.74	0.00
	MM * TRJ.NO ₂ .Wsea	11	4,349,657	395,423	2.64	0.00
	TRJ.WV.Wsea * ShipNo	1	1,285,439	1,285,439	8.58	0.00

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
	TRJ.SO ₂ .Wsea * TRJ.BaP	1	939,759	939,759	6.27	0.01
	TRJ.CO ₂ .Wsea	1	828,503	828,503	5.53	0.02
	TRJ.NO.Wsea * TRJ.NO ₂ .Wsea	1	581,286	581,286	3.88	0.05
	Error	501	75,080,225	149,861		
	Total	517	83,181,175			
TRJ_sum_J37_J39	Intercept	1	3,075,655	3,075,655	149.96	0.00
	TRJ.RAIN.Wsea Y_N * TRJ.BaP	1	390,954	390,954	19.06	0.00
	YYYY * TRJ.PRES.Wsea	6	1,033,366	172,228	8.40	0.00
	TRJ.HUMID.Wsea * ShipNo	1	98,673	98,673	4.81	0.03
	DD * TRJ.WV.Wsea	30	934,326	31,144	1.52	0.04
	Error	388	7,957,634	20,509		
	Total	426	10,274,790			
TRJ_sum_J40_J42	Intercept	0				
	MM * YYYY	59	566,709.4	9605.24	4.47	0.00
	TRJ.PM _{2.5} .Wsea * TRJ.HUMID.Wsea	1	42,343.8	42,343.81	19.70	0.00
	TRJ.PM ₁₀ .Wsea * TRJ.PM _{2.5} .Wsea	1	52,778.5	52,778.49	24.55	0.00
	TRJ.RAIN.Wsea Y_N * TRJ.PRES.Wsea * ShipNo	1	27,068.1	27,068.15	12.59	0.00
	TRJ.NO _x .Wsea * TRJ.HUMID.Wsea	1	35,865.6	35,865.56	16.68	0.00
	TRJ.WV.Wsea * TRJ.HUMID.Wsea	1	9744.2	9744.21	4.53	0.04
	TRJ.RAIN.Wsea Y_N * TRJ.TEMP.Wsea	1	32,337.0	32,337.02	15.04	0.00
	TRJ.RAIN.Wsea Y_N * TRJ.WV.Wsea	1	9,366.3	9366.31	4.36	0.04
	Error	86	184,875.7	2149.72		
	Total	152	885,028.9			
TRJ_sum_J43_J44	Intercept	1	3,753,231	3,753,231	252.50	0.00
	TRJ.TEMP.Wsea	1	271,379	271,379	18.26	0.00
	TRJ.NO _x .Wsea * TRJ.WV.Wsea	1	254,833	254,833	17.14	0.00
	TRJ.RAIN.Wsea Y_N * TRJ.TEMP.Wsea	1	60,995	60,995	4.10	0.04
	Error	539	8,011,803	14,864		
	Total	542	8,866,679			
TRJ_sum_J45_J46	Intercept	1	524,440	524,440	6.52	0.01
	TRJ.WV.Wsea * ShipNo	1	1,119,519	1,119,519	13.92	0.00
	TRJ.NO ₂ .Wsea * TRJ.PRES.Wsea	1	1,045,380	1,045,380	13.00	0.00
	TRJ.PM ₁₀ .Wsea * TRJ.PM _{2.5} .Wsea	1	487,696	487,696	6.06	0.01
	TRJ.PRES.Wsea	1	613,985	613,985	7.63	0.01
	TRJ.RAIN.Wsea Y_N * TRJ.PM _{2.5} .Wsea	1	406,014	406,014	5.05	0.03
	Error	541	43,517,973	80,440		
	Total	546	46,264,315			
TRJ_J47	Intercept	1	1,569,279	1,569,279	1260.80	0.00
	YYYY * TRJ.BaP	6	36,685	6114	4.91	0.00
	DD * TRJ.BaP	28	73,109	2611	2.10	0.00
	YYYY * TRJ.NO.Wsea	6	18,660	3110	2.50	0.03
	Error	87	108,287	1245		
	Total	127	252,386			
TRJ_I20	Intercept	1	16,804,098	16,804,098	561.34	0.00
	TRJ.NO _x .Wsea * TRJ.WV.Wsea	1	204,850	204,850	6.84	0.01
	TRJ.RAIN.Wsea Y_N * TRJ.TEMP.Wsea	1	194,479	194,479	6.50	0.01
	Error	538	16,105,371	29,936		

Dependent Variable	Effect	Degr. of Freedom	SS	MS	F	p
	Total	540	16,442,128			
TRJ_sum_I21_I23	Intercept	0	0			
	TRJ.NO ₂ .Wsea * TRJ.BaP	1	93,830	93,829.63	5.52	0.02
	MM * YYYY	65	1,656,422	25,483.42	1.50	0.01
	Error	498	8,467,580	17,003.17		
TRJ_sum_I65_I66	Intercept	1	610,483	610,482.7	24.57	0.00
	TRJ.O ₃ .Wsea * TRJ.WV.Wsea	1	457,989	457,988.7	18.43	0.00
	TRJ.CO ₂ .Wsea * ShipNo	1	265,805	265,804.8	10.70	0.00
	Error	369	9,169,514	24,849.6		
	Total	371	9,795,077			

Author Contributions: Piotr O. Czechowski—draft preparation, quantitative analysis, software, data validation, modeling, writing; Piotr Dąbrowiecki—draft preparation, medical analysis, data, writing; Aneta Oniszczyk-Jastrzębek—draft preparation, economic analysis, validation, writing; Michalina Bielawska—environmental analysis, obtaining data; Ernest Czernański—draft preparation, economic analysis, validation, writing, final editing; Tomasz Owczarek—quantitative analysis, modeling; Patrycja Rogula-Kopiec—environmental analysis, obtaining data; Artur Badyda—environmental analysis, obtaining data, writing, final editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Conflicts of Interest: The authors declare no conflict of interest

References

- Badyda, A.; Dąbrowiecki, P.; Czechowski, P.O.; Majewski, G. Risk of bronchi obstruction among non-smokers—Review of environmental factors affecting bronchoconstriction. *Respir. Physiol. Neurobiol.* **2015**, *209*, 39–46.
- Czechowski, P.O. *New Methods and Models of Data Measurement Quality in Air Pollution Monitoring Networks Assessment*, 1st ed.; Gdynia Maritime University Press: Gdynia, Poland, 2013.
- United Nations Population Fund. “State of World Population 2019”; UNFPA: New York, NY, USA, 2019; ISBN 978-0-89714-029-4, 2019.
- WHO Global Ambient Air Quality Database (update 2018). Available online: <https://www.who.int/airpollution/data/en/> (accessed on 4 December 2019).
- Directive 2004/107/EC of the European Parliament and of the Council of 15 December 2004 relating to arsenic, cadmium, mercury, nickel and polycyclic aromatic hydrocarbons in ambient air. *Off. J. Eur. Commun.* **2005**, *23*, 3–16.
- Directive 2008/50/EC of the European Parliament and of the Council of 21 May 2008 on ambient air quality and cleaner air for Europe. *Off. J. Eur. Commun.* **2008**, *152*, 1.
- Kunzli, N.; Perez, L.; Rapp, R. *Air Quality and Health*; ERS Environment & Health Committee: Lausanne, Switzerland, 2010.
- Kelly, F.J.; Fussell, J.C. Air pollution and airway disease. *Clin. Exp. Allergy* **2011**, *41*, 1059–1071.
- Zanobetti, A.; Antonella, M.; Bind, A.; Schwartz, J. Particulate air pollution and survival in a COPD cohort. *Environ. Health* **2008**, *7*, 48.
- Vallero, D.A. *Fundamentals of Air Pollution*, 4th ed.; Academic Press: Cambridge, MA, USA, 2014. Available online: <http://www.sciencedirect.com/science/book/9780123736154> (accessed on 18 December 2019).
- Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **2013**, *380*, 2095–2128. Available online: <https://ginasthma.org/2018-gina/> (accessed on 18 December 2019).
- Möller, A.; Agius, R.; de Vocht, F.; Lindley, S.; Gerrard, W.; Custovic, A.; Simpson, A. Effects of long-term exposure to PM₁₀ and NO₂ on asthma and wheeze in a prospective birth cohort. *J. Epidemiol. Community Health* **2014**, *68*, 21–28.

13. Mejza, F.. Przewlekła obturacyjna choroba płuc (POCHP). *Med. Praktyczna* **2010**, *11*, 04.
14. Ko, F.W.; Hui, D.S. Air pollution and chronic obstructive pulmonary disease. *Respirology* **2012**, *17*, 395–401, doi:10.1111/j.1440-1843.2011.02112.x. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/22142380> (accessed on 18 December 2019).
15. Śliwiński, P.; Górecka, D.; Jassem, E.; Pierzchała, W. Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. *Pneumonol. Alergol.* **2014**, *82*, 227–263.
16. Dąbrowiecki, P.; Mucha, D.; Gayer, A.; Adamkiewicz, Ł.; Badyda, A. "Assessment of Air Pollution Effects on the Respiratory System Based on Pulmonary Function Tests Performed During Spirometry Days". *Adv. Exp. Med. Biol.* **2015**, *873*, 43–52, doi:10.1007/5584_2015_152.
17. Andersen, Z.J.; Hvidberg, M.; Jensen, S.S.; Ketzel, M.; Loft, S.; Sørensen, M.; Tjønneland, A.; Overvad, K.; Raaschou-Nielsen, O. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: A cohort study. *Am. J. Respir. Crit. Care Med.* **2011**, *183*, 455–461.
18. Hnizdo, E.; Sullivan, P.A.; Bang, K.M.; Wagner, G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: A study of data from the Third National Health and Nutrition Examination Survey. *Am. J. Epidemiol.* **2002**, *156*, 738–746.
19. MacIntyre, E.A.; Gehring, U.; Mölter, A.; Fuerte, E.; Klümper, C.; Krämer, U.; Quass, U.; Hoffmann, B.; Gascon, M.; Brunekreef, B.; et al. Air pollution and respiratory infections during early childhood: An analysis of 10 European birth cohorts within the ESCAPE Project. *Environ. Health Perspect.* **2014**, *122*, 107–113.
20. Simoni, M.; Baldacci, S.; Maio, S.; Cerrai, S.; Sarno, G.; Viegi, G. Adverse effects of outdoor pollution in the elderly. *J. Thorac. Dis.* **2015**, *7*, 34–45.
21. Halonen, J.I.; Lanki, T.; Yli-Tuomi, T.; Tiittanen, P.; Kulmala, M.; Pekkanen, J. Particulate air pollution and acute cardiorespiratory hospital admissions and mortality among the elderly. *Epidemiology* **2009**, *20*, 143–153.
22. Qiu, H.; Tian, L.W.; Pun, V.C.; Ho, K.; Wong, T.W.; Ignatius, T.S. Coarse particulate matter associated with increased risk of emergency hospital admissions for pneumonia in Hong Kong. *Thorax* **2014**, *69*, 1027–1033.
23. Neupane, B.; Jerrett, M.; Burnett, R.T.; Marrie, T.; Arain, A.; Loeb, M. Long-term exposure to ambient air pollution and risk of hospitalization with community-acquired pneumonia in older adults. *Am. J. Respir. Crit. Care Med.* **2010**, *181*, 47–53.
24. Hermanowski, T.; Drozdowska, A. Ocena wartości życia i zdrowia, pomiar korzyści związanych z technologiami medycznymi, rodzaje kosztów w opiece zdrowotnej. In *Szacowanie Kosztów Społecznych Choroby i Wpływu Stanu Zdrowia na Aktywność Zawodową i Wydajność Pracy*; Hermanowski, T., Ed.; ABC Wolters Kluwe Business: Warszawa, Poland, 2013; pp. 13–30.
25. WHO. *Guide to Identifying the Economic Consequences of Disease and Injury*; World Health Organization, Department of Health Systems Financing, Health Systems and Services: Geneva, Switzerland, 2009.
26. Krol, M.; Brouwer, W.B.; Severens, J.; Kaper J.; Evers, S. Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effect. *Soc. Sci. Med.* **2012**, *75*, 1981–1988.
27. Czermański, E. *Morska Żegluga Kontenerowa a Zrównoważony Rozwój Transportu*; Wydawnictwo Instytutu Transportu i Handlu Morskiego Uniwersytetu Gdańskiego: Gdańsk, Poland, 2019; pp. 30–41.
28. Council of the European Union. Council Directive 1999/32/EC of 26 April 1999 Relating to a Reduction in the Sulphur Content of Certain Liquid Fuels and 25Amending Directive 93/12/EEC. *Off. J. Eur. Commun.* **1999**, *121*, 0013–0018.

